Equillium (EQ) Non-Current Assets (2017 - 2026)
Equillium (EQ) reported Non-Current Assets of $808000.0 for Q1 2026, up 57.5% year-over-year from $513000.0 in Q1 2025, and down 4.83% quarter-over-quarter from $849000.0 in Q4 2025.
Equillium (EQ) Non-Current Assets (2017 - 2026) Analysis & Trends
Equillium (EQ) has 10 years of Non-Current Assets data on file, last reported at $808000.0 in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $808000.0, up 57.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (up 3.66% YoY), and the FY2025 annual result was $849000.0, up 35.62% from the prior year.
- Non-Current Assets declined to $808000.0 in Q1 2026 per EQ's latest filing, from $849000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $2.2 million in Q1 2022 and troughed at $447000.0 in Q2 2025.
- A 5-year average of $1.2 million and a median of $1.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 864.13% in 2022, then sank 54.11% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $1.7 million in 2022, then declined by 29.95% to $1.2 million in 2023, then slumped by 46.99% to $626000.0 in 2024, then soared by 35.62% to $849000.0 in 2025, then decreased by 4.83% to $808000.0 in 2026.
- Business Quant data shows EQ's Non-Current Assets at $808000.0 in Q1 2026, $849000.0 in Q4 2025, and $927000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | 808,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 808,000.00 |
| Dec 31, 2025 | 849,000.00 |
| Sep 30, 2025 | 927,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Dec 31, 2024 | 626,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Jun 30, 2024 | 974,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 1.86 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | 2.15 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Sep 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 271,000.00 |